Cerebral infarction has high morbidity, high recurrence rate and high disability rate. Currently, there is no absolutely effective drug for the treatment of cerebral infarction, and it should be selected according to different morbidity period, etiology and pathogenesis. The best drugs are thrombolytic drugs such as recombinant human tissue-type plasminogen activator (rt-PA) and urokinase, but these drugs can only be applied in the hyperacute stage, and there is no contraindication for patients. rt-PA intravenous thrombolysis can be applied within 4.5 hours of the onset of the disease, and urokinase thrombolysis can be applied within 6 hours of the onset of the disease, which can be used to save cerebral cells by dissolving the thrombus that has been formed in local acute stage and restoring blood flow to the cerebral tissues of the ischemic part in the early stage. These drugs can restore blood flow to the brain tissue in the early ischemic area by dissolving the locally formed thrombus to save brain cells. However, thrombolytic drugs are not absolutely effective and may increase the risk of bleeding. If the time window for thrombolytic therapy has been missed when the patient visits the clinic, appropriate therapeutic measures should be taken according to the cause of the disease: for example, patients with atherosclerosis should be treated with antiplatelet aggregation (commonly used aspirin, clopidogrel bisulfate tablets, etc.) and lipid-lowering to stabilize plaques (usually statins), and patients with embolism should be treated with anticoagulant therapy (intravenous pumping of normal heparin, subcutaneous injection of low molecular heparin, and oral warfarin for patients with atrial fibrillation), and so on. The treatment is also supplemented by improving cerebral circulation and nutritional support. At the same time, it is supplemented with comprehensive treatment measures such as improving cerebral circulation and nourishing brain cells, so as to try to save brain tissues and preserve neurological functions. In addition, since patients with cerebral infarction are often accompanied by hypertension, diabetes mellitus, hyperlipidemia, hyperhomocysteinemia and other high-risk factors, these risk factors should be controlled at the same time, and the corresponding antihypertensive, hypoglycemic and hypolipidemic drugs should be applied under the guidance of doctors, among which the hypolipidemic drugs usually apply statins, and the hypohomocysteine-reducing drugs should be selected to use the combined drugs of folic acid, vitamin B6 and vitamin B12. In conclusion, the best medicine for cerebral infarction is to apply thrombolytic drugs in the ultra-early stage, however, this time is very limited and must ensure that the patient has no contraindications, and most of the time, the treatment of cerebral infarction should be based on the cause of the disease, the time of onset of the disease and other choices of individualized treatment plan, comprehensive treatment.